Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TUCATINIB for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 57 adverse event reports in the FDA FAERS database where TUCATINIB was used for Neoplasm malignant.

Most Reported Side Effects for TUCATINIB

Side Effect Reports % Deaths Hosp.
Diarrhoea 1,587 26.3% 73 406
Nausea 862 14.3% 29 273
Fatigue 843 14.0% 49 216
Vomiting 483 8.0% 24 204
Death 400 6.6% 399 88
Off label use 392 6.5% 31 112
Malignant neoplasm progression 361 6.0% 37 26
Palmar-plantar erythrodysaesthesia syndrome 355 5.9% 16 49
Product dose omission issue 332 5.5% 19 122
Asthenia 322 5.3% 34 134
Decreased appetite 286 4.7% 16 67
Metastases to central nervous system 270 4.5% 26 61
Disease progression 268 4.4% 40 62
Dehydration 239 4.0% 9 154
Neoplasm progression 237 3.9% 35 37

Other Indications for TUCATINIB

Breast cancer female (1,890) Her2 positive breast cancer (993) Product used for unknown indication (825) Breast cancer metastatic (738) Breast cancer (552) Metastases to central nervous system (77) Colorectal cancer metastatic (52) Colon cancer (49) Invasive breast carcinoma (38) Invasive ductal breast carcinoma (38)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

TUCATINIB Full Profile All Neoplasm malignant Drugs TUCATINIB Demographics TUCATINIB Timeline